NCT03700905 Other Study ID Numbers: CA209-934 : First Posted: October 9, 2018 Key Record Dates: Last Update Posted: December 11, 2020 Last Verified: December 2020 Individual Participant Data (IPD) Sha
Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy - No Study Results Posted.
Study NCT03700905 Submitted Date: October 8, 2018 (v1) Study Identification. Unique Protocol ID: CA209-934 : Brief Title: Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs
Primary endpoint is DFS and secondary endpoint includes locoregional control (LRC) and overall survival (OS). This study is one of the first in HNSCCs implementing immunotherapy in first-line treatmen
Surgically treated locally advanced head and neck squamous cell carcinoma often requires postoperative chemoradiation with high risk of acute and late toxicity. DFS after 2 years is approximately 70%.
NCT03700905, CA209-934: Conditions. Head and Neck Cancer. Treatments. Surgical resection of primary tumor, Adjuvant radio(-chemo)therapy, Neoadjuvant Nivolumab, Adjuvant Nivolumab, Adjuvant Nivolumab
Inclusion Criteria: Informed of the investigational nature of this study and give written informed consent; Histologically or cytologically confirmed nasopharyngeal carcinoma, tumor staged as IVB (acc
Clinical trial for head and neck cancer , Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy
Jul 1, 2022Introduction. Squamous cell carcinoma of the head and neck (HNSCC) is one of the most common malignancies in the world, accounting for over 90% of head and neck tumors in Asia and Europe []
NCT03700905: Phase 3: Interventional: No Results: Posted: 2018-10-09: Start: 2018-08-21: Results: None: Primary: None: Complete: None: Brief Summary: Multicenter randomized controlled phase III study
Sep 9, 2020Another phase 3 clinical study, IMSTAR-HN (NCT03700905) is evaluating the potential of nivolumab, alone or in combination with ipilimumab, as immunotherapy vs standard follow up in surgical
TPS6095 Background: Surgically treated locally advanced head and neck squamous cell carcinoma (LA HNSCC) often requires postoperative chemoradiation with high risk of acute and late toxicity. Disease-
Nov 26, 2020Antibody Structure. B-lymphocyte cells are instructed by numerous immunogens, such as bacteria, viruses, fungi, parasites, cellular antigens, chemicals, and synthetic substances to differe
Abstract. Cancer immunotherapies utilizing immune checkpoint inhibitors (ICI) have demonstrated durable efficacy in a proportion of patients with advanced/metastatic cancers. More recently, the use of
The pairing of radiotherapy with ICI is currently being tested in a variety of settings across a range of solid tumour types (NCT02239900, NCT03700905, NCT03867175 and NCT03693014).
Mar 3, 2021Main text. About 90% of head and neck cancers occur as head and neck squamous cell carcinoma (HNSCC). According to the global cancer statistics of 2018,1 more than 830,000 new HNSCC cases a
Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, United States. Frontiers in Oncology , 01 Jan 2020, 10: 608772. DOI: 10.3389/fonc.2
Changing Paradigms in Head and Neck Cancer. Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity, oropharynx, and larynx/hypopharynx, is the sixth most incident can
Mar 5, 2021Preclinical data suggest that head and neck squamous cell carcinomas (HNSCC) may evade immune surveillance and induce immunosuppression. One mechanism of immune evasion involves the express